3.2. Changes in Anthropometric, Metabolic and Cardiovascular Profiles
Anthropometric, metabolic and cardiovascular characteristics of participants divided by Altilix group and placebo group are presented in After six months of treatment, we found a significant reduction in body weight but not in waist circumference in the Altilix group compared to placebo. All glycemic and lipid parameters showed a significant improvement in the Altilix group compared to placebo, with the only exception being HDL-cholesterol. The percentage changes of anthropometric, glycemic and lipid parameters in both groups receiving Altilix and placebo are shown in As shown in 